The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Condition	Treatment or Intervention	Phase
Schizophrenia	Drug: Investigational Schizophrenia Drug	Phase III

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion criteria:

• If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
• Diagnosis of Schizophrenia
• Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.

Exclusion criteria:

• Patients who are currently taking or have taken antidepressant medication in the last month prior.
• Patients who are or have been suicidal or homicidal in the last 6 months.
• Patients with a history of autistic disorder or another pervasive developmental disorder
• Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition

Arkansas
      Little Rock,  Arkansas,  72211,  United States; Recruiting
California
      Garden Grove,  California,  90804,  United States; Recruiting
      Study Site (005), Rosemead,  California,  91770,  United States; Recruiting
      La Mesa,  California,  91942,  United States; Recruiting
      Oceanside,  California,  92056,  United States; Recruiting
      San Diego,  California,  92105,  United States; Recruiting
      Study Site (020), San Diego,  California,  92126,  United States; Recruiting
Connecticut
      Study Site (008), Hartford,  Connecticut,  06106,  United States; Terminated
Florida
      Winter Park,  Florida,  32789,  United States; Recruiting
      North Miami,  Florida,  33161,  United States; Recruiting
      Miami,  Florida,  33161,  United States; Recruiting
Georgia
      Atlanta,  Georgia,  30308,  United States; Not yet recruiting
Illinois
      Granite City,  Illinois,  62040,  United States; Recruiting
Maryland
      Rockville,  Maryland,  20850,  United States; Recruiting
      Glen Burnie,  Maryland,  21061,  United States; Recruiting
Massachusetts
      Study Site (009), Boston,  Massachusetts,  02114,  United States; Recruiting
Nevada
      Study Site (022), Reno,  Nevada,  89512,  United States; Terminated
New Jersey
      Study Site (023), Kenilworth,  New Jersey,  07033,  United States; Recruiting
      Clementon,  New Jersey,  08021,  United States; Recruiting
New York
      Study Site (021), Orangeburg,  New York,  10962,  United States; Recruiting
      Study Site (012), Rochester,  New York,  14620,  United States; Recruiting
North Carolina
      Study Site (015), Butner,  North Carolina,  27509,  United States; Recruiting
      Study Site (014), Raleigh,  North Carolina,  27603,  United States; Recruiting
      Study Site (024), Raleigh,  North Carolina,  27609,  United States; Terminated
      Study Site (003), Charlotte,  North Carolina,  28211,  United States; Recruiting
Ohio
      Study Site (004), Cleveland,  Ohio,  44106,  United States; Terminated
      Beachwood,  Ohio,  44122,  United States; Recruiting
      Lyndhurst,  Ohio,  44124,  United States; Recruiting
Pennsylvania
      Norristown,  Pennsylvania,  19401,  United States; Recruiting
Texas
      Desoto,  Texas,  75115,  United States; Recruiting
      Bellaire,  Texas,  77401,  United States; Recruiting
      Austin,  Texas,  78756,  United States; Recruiting
Utah
      Study Site (018), Salt Lake City,  Utah,  84117,  United States; Recruiting
Wisconsin
      Study Site (010), Milwaukee,  Wisconsin,  53226,  United States; Recruiting

Study ID Numbers:  SCA30926
Record last reviewed:  October 2004
Record first received:  October 30, 2003
ClinicalTrials.gov Identifier:  NCT00071747
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10